- Reported mixed Q2 results. Co then disclosed a manufacturing issue: a suboptimal batch of in-process intermediate was used to produce two lots of bempegaldesleukin, which ultimately led to the softening of response rates in the PIVOT-02 study. The issue was restricted to the single batch of intermediates using lots two and five. Co has developed a comprehensive control strategy to limit variances in raw materials, intermediates, and the final product going forward. Downgraded at Mizuho, Jefferies, and JP Morgan. At two-year lows.
Nektar Therapeutics beats by $0.17, misses on revs